Q1 2022 Results
Company overview
Financial performance
Financial review
2022 priorities
Innovation: Pipeline overview
Novartis pipeline in Phase 2
Solid Tumors
Code
Name
AAA601
LutatheraⓇ
Mechanism
Indication(s)
Radioligand therapy target SSTR GEPNET, pediatrics
1L ES-SCLC
Glioblastoma
BLZ945
sotuletinib
DRB436 Tafinlare + Mekinist®
TabrectaⓇ
CSF-1R inhibitor
BRAF inhibitor + MEK inhibitor
Met inhibitor
KRAS inhibitor
INC280
JDQ443
JDQ443
NIR178
NIS793
NIR178, spartalizumab
NIS793
Ad2AR inhibitor, PD1 inhibitor
TNO155 TNO155
TGFB1 inhibitor
SHP2 inhibitor
Solid tumors
HGG/LGG, pediatrics
Non-small cell lung cancer (Combo)
NSCLC (combo)
Cancers
1L metastatic colorectal cancer
Solid tumors (single agent)
Immunology
Hidradenitis suppurativa
Code
Name
Mechanism
AIN457 Cosentyx®
IL17A inhibitor
Indication(s)
Lichen planus
CFZ533
iscalimab
CD40 inhibitor
Sjögren's
Liver Tx
CMK389 CMK389
DFV890 DFV890
IL-18 inhibitor
Atopic dermatitis
NLRP3 inhibitor
Osteoarthritis
LJN452 tropifexor + licogliflozin
LNA043 LNA043
LOU064 remibrutinib
FXR agonist
Familial cold auto-inflammatory syndrome
Non-alcoholic steatohepatitis (Combos)
ANGPTL3 agonist
Knee osteoarthritis
BTK inhibitor
Sjögren's
LRX712 LRX712
LYS006 LYS006
Anti-inflammatory
MAS825 MAS825
MHV370 MHV370
VAY736 ianalumab
BAFF-R inhibitor
Neuroscience
Code
Name
ADPT06 ADPT06
Mechanism
BLZ945
DLX313
LMI070
sotuletinib
DLX313 (UCB0599)
branaplam
CSF-1R inhibitor
Alpha-synuclein Inhibitor
mRNA splicing modulator
MIJ821
MIJ821
NR2B negative allosteric
modulator
39 Investor Relations | Q1 2022 Results
Hematology
Appendix
Innovation: Clinical trials
References
Abbreviations
30 lead indications
Lead indication
Mechanism
BCR-ABL inhibitor
Code
ABL001 ScemblixⓇ
INC424 Jakavi®
Name
JAK1/2 inhibitor
LNP023
iptacopan
CFB inhibitor
MBG453 sabatolimab
PHE885 PHE885
PKC412 Rydapte
TIM3 antagonist
BCMA cell therapy
Multi-targeted kinase inhibitor
Cardiovascular, Renal, Metabolism
Code
Name
CFZ533 iscalimab
Mechanism
CD40 inhibitor
HSY244 HSY244
LNP023 iptacopan
MBL949 MBL949
CFB inhibitor
Indication(s)
Chronic myeloid leukemia, 2L, pediatrics
Myelofibrosis (combo)
Autoimmune cytopenias
Unfit acute myeloid leukaemia
Acute GVHD,
pediatrics
Chronic GVHD,
pediatrics
Acute myeloid leukaemia, maintenance
4L multiple myeloma
Acute myeloid leukemia, pediatrics
Indication(s)
Lupus nephritis Type 1 diabetes mellitus
Atrial fibrillation
Membranous nephropathy
Obesity related diseases.
Osteoarthritis
Acne
Osteoarthritis (combos)
Colitis ulcerative
Hidradenitis suppurativa
Hidradenitis suppurativa
NLRC4-GOF indications
Sjögren's
Sjögren's
Systemic lupus erythematosus
Indication(s)
Cognitive impairment
Amyotrophic lateral sclerosis
Parkinson's disease
Huntington's disease
Mixed connective tissue disease
Autoimmune hepatitis
Major depressive disorder with acute suicidal ideation or behavior
Others
Code Name
Global Health
KAE609 cipargamin
KAF156 ganaplacide
LXE408 LXE408
SEG101 Adakveo®
Respiratory & Allergy
CMK389
CSJ117
CMK389
ecleralimab
QBW251 icenticaftor
QMF149 Atectura®
Ophtalmology
CPK850 CPK850
LKA651 LKA651
PPY988 PPY988
SAF312 libvatrep
UNR844 UNR844
Mechanism
PfATP4 inhibitor
Proteasome inhibitor
P-selectin inhibitor
IL-18 inhibitor
TSLP inhibitor
CFTR potentiator
Combo
RLBP1 AAV
EPO inhibitor
Gene therapy
TRPV1 antagonist
Reduction of disulfide bonds
Indication(s)
Malaria, severe
Malaria, uncomplicated
Visceral leishmaniasis
Malaria, uncomplicated
Sickle cell anaemia with crisis, pediatrics
Pulmonary sarcoidosis
Asthma
Chronic obstructive pulmonary disease
Bronchiectasis
Chronic obstructive pulmonary disease
Asthma, pediatrics
Retinitis pigmentosa
Diabetic retinopathy
Geographic atrophy
Chronic ocular surface pain
Presbyopia
U NOVARTIS | Reimagining MedicineView entire presentation